FDA Oncology Announcements

FGFR inhibitor × Gastrointestinal × Clear all

4 Announcements

FDA grants accelerated approval to futibatinib for cholangiocarcinoma

Drug: Lytgobi (futibatinib) · FGFR inhibitor
Condition: Gastrointestinal

FDA grants accelerated approval to infigratinib for metastatic cholangiocarcinoma

Drug: Truseltiq (infigratinib) · FGFR inhibitor
Condition: Gastrointestinal

FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion

Drug: PEMAZYRE (pemigatinib) · FGFR inhibitor
Condition: Gastrointestinal

FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion

Drug: PEMAZYRE (pemigatinib) · FGFR inhibitor
Condition: Gastrointestinal